We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser’s cookie settings at any time. Please review our privacy policy for more information. OK
"Management continuity and alignment with shareholders should be the priorities of your compensation program early on."
–Jim Heim, Managing Director, Boston
Pearl Meyer’s senior consultants are both experienced and passionate about working with early stage companies across a variety of high-growth sectors. Our industry experience working with both public and private companies across various stages in their business life cycle gives us the insight and expertise to apply a long-term vision to compensation planning. We believe that where your compensation strategy begins drives your success as your business evolves.
Companies that are successful in creating innovative business models are able to maintain competitive advantage as they grow by partnering with Pearl Meyer to create compensation programs that are aligned with their long-term strategy for value creation.
Pearl Meyer offers portfolio companies and their owners an unparalleled level of expertise in designing compensation programs that help you keep your best talent and protect your capital investment. Our goal is to guide your compensation strategy through each stage in preparation for an IPO or other exit event.
Pearl Meyer works with public and private companies in the technology industry who face the challenges of a fast-paced environment where retaining and rewarding the best and brightest while motivating them to succeed is critical to survival. We create compensation strategies that change compensation from a cost of doing business to a competitive advantage by aligning your business and talent strategy with your long term goals for value creation.
Companies in the life science sector are navigating a range of business imperatives, such as shifts in trials and approvals requirements, the flight of venture capital to “safer” sectors, reimbursement and market access constraints, and pressure to discover and commercialize therapies more quickly and at significantly lower expense.
Whether your company is well-established or newly-emerging, these issues influence your business and are critical to compensation and governance decision-making. Pearl Meyer works with life science companies, providing advice on creating philosophies, programs and strategies that enable breakthrough performance.